#China #Shanghai #Biopharmaceutical #AsymBio #Technology Platforms

AsymBio Introduces Integrated Biopharmaceutical Technology Platforms

AsymBio, a subsidiary of the renowned Asymchem Group, has recently taken a significant step forward in the biopharmaceutical industry. The company announced the establishment of integrated technology platforms designed to cover the full spectrum of the biopharmaceutical development lifecycle. This initiative aims to provide innovative, efficient, and client-focused solutions for biopharmaceutical development.

Comprehensive Services for Biopharmaceutical Development

AsymBio positions itself as a technology-driven Contract Development and Manufacturing Organization (CDMO) devoted to enhancing innovation by integrating development and manufacturing services. Their offerings span an impressive range of platforms, each designed to address crucial aspects of biopharmaceutical development:

AmigoCHO™ Cell Line Development Platform

This platform supports the creation of high-titer and stable clones, which are critical for ensuring quality production in biopharmaceuticals. It encompasses everything from cell pool establishment to clone selection and stability analysis, providing a robust foundation for subsequent processes.

Upstream Process Development Platform

AsymBio's upstream platform is engineered to optimize processes and facilitate scale-up. It enables rapid workflows from preclinical materials prep to process characterization and technology transfer. Notably, project timelines can be reduced to as short as nine weeks, a significant advantage in the fast-paced biotech landscape.

Downstream Process Development Platform

The downstream capabilities focus on enhancing product purity while minimizing impurities and maximizing yield. This platform covers advanced development techniques such as chromatography and filtration, crucial for ensuring that products meet rigorous quality standards.

Conjugation Toolbox

The Conjugation Toolbox allows for fast development and optimization of diverse conjugation processes used in creating bioconjugates. This modular system supports a variety of methods, including enzymatic techniques and glyco-remodeling. Its recognition at the World ADC Awards as a top platform underscores its innovative approach.

IMPACT Drug Product Development Platform

The IMPACT platform offers tailored drug product development services that cater to specific indications and phases of development. This includes specialized formulations for high-potency biologics and high-concentration presentations, ensuring products are both effective and commercially viable.

Payload-Linker CMC Development Platform

Focusing on CMC (Chemistry, Manufacturing, and Controls) development, AsymBio’s platform offers multiple payload and linker options. Its extensive experience supports the development of numerous IND and NDA projects, reflecting a depth of expertise in complex biopharmaceutical developments.

Comprehensive Analytical Platform

This platform provides in-depth analytical method development and product characterization, ensuring all critical quality attributes are meticulously assessed throughout the product lifecycle. It combines capabilities from physicochemical testing, mass spectrometry, and bioassays to offer a comprehensive analysis.

Commitment to Innovation and Excellence

AsymBio is dedicated to continuing investments in R&D and technology development. By merging advanced scientific techniques with extensive manufacturing experience, the company aims to tackle the complex challenges facing the biopharmaceutical sector. Their commitment helps in improving manufacturing efficiency, enhancing product quality, and supporting successful commercial launches for innovative therapies on a global scale.

About AsymBio

With over 25 years of industry experience, AsymBio stands out in the biopharmaceutical CDMO space. The company offers comprehensive services, from early-stage development through clinical trials to commercial-scale production. As AsymBio expands its offerings beyond antibody-drug conjugates into novel drug formats, it continues to reaffirm its role as a leader in biopharmaceutical manufacturing.

For more information about AsymBio and its innovative services, visit www.asymbio.com or follow them on LinkedIn.